z-logo
open-access-imgOpen Access
Treatment outcomes among patients with metastatic uveal melanoma: a retrospective monocentric study
Author(s) -
Iryna Zherka Iryna,
Larisa Naumenko,
Katsiaryna Zhyliayeva,
Alesia Evmenenko,
Vladislau Korsik,
А.С. Портянко
Publication year - 2022
Publication title -
voprosy onkologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.108
H-Index - 11
eISSN - 2949-4915
pISSN - 0507-3758
DOI - 10.37469/0507-3758-2022-68-2-224-231
Subject(s) - medicine , melanoma , cancer , radiation therapy , immunotherapy , chemotherapy , oncology , cancer registry , survival rate , retrospective cohort study , metastatic melanoma , surgery , cancer research
Aim: to establish the dependence of cancer specific survival rate of patients with metastatic uveal melanoma on the treatment method, according to the Belarusian Cancer Registry.Material and methods. We analyzed the data of the Belarusian cancer registry and medical records of patients diagnosed with metastatic uveal melanoma in the period from 2006 to 2015. Treatment methods included chemotherapy, radiation therapy, surgical removal of metastases, immunotherapy with roncoleukin. Hepatotropic therapy included hepatic artery chemoembolization, radiofrequency ablation of metastatic foci, or liver resection. We analyzed cancer specific 1-, 3-, 5- and 10-year survival of patients in treatment groups.Results. The median cancer specific survival of patients who received only supportive care was 2.0 (95% CI 1.1–2.9) months, after any of the anticancer therapy methods application — 10.0 (95% CI 7.3–12.7) months. The median cancer specific survival in the chemotherapy group was 9.0 (95% CI 6.3–11.7) months, in the case of hepatotropic therapy — 20.0 (95% CI 10.9–29.1). The median cancer specific survival of patients receiving immunotherapy was 7.0 (95% CI 1.1–12.9), the survival plateau was reached after 48 months.Conclusion. Metastatic uveal melanoma is characterized by a poor prognosis, including during therapy. Both hepatotropic and systemic therapy have limited efficacy. Further study of the tumor biology and immune microenvironment is required in order to determine possible targets of exposure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here